Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a limited number of selective targets that can be exploited for antifungal drug development. This has also resulted in a very restricted number of antifungal drugs that are clinically available for the treatment of invasive fungal infections at the present time—polyenes, azoles, echinocandins, and flucytosine. Moreover, the utility of available antifungals is limited by toxicity, drug interactions and the emergence of resistance, which contribute to high morbidity and mortality rates. This review will present a brief summary on the landscape of current antifungals and those at different stages of clinical development. We will also briefly touch upon potential new targets and opportunities for novel antifungal strategies to combat the threat of fungal infections.

中文翻译：

---

当前的抗真菌药，抗真菌治疗的新前景和未来方法。

真菌感染对越来越多的免疫和医学受损患者构成威胁。真菌是真核生物，因此，可用于抗真菌药物开发的选择性靶标数量有限。这也导致目前临床上可用于治疗侵袭性真菌感染的抗真菌药物数量非常有限，包括多烯类，唑类，棘霉素和氟胞嘧啶。而且，可用的抗真菌药的用途受到毒性，药物相互作用和耐药性的限制，这会导致较高的发病率和死亡率。这篇综述将简要介绍当前抗真菌药的概况以及处于临床发展不同阶段的抗真菌药。